PETALING JAYA: Three thousand Malaysian adults will be invited to participate in the phase three clinical trials for a new vaccine manufactured by Chinese firm Shenzhen Kangtai Biological Products Co Ltd, says the Health Ministry. Health director-general Tan Sri Dr Noor Hisham Abdullah said the clinical study involving the inactivated vaccine was approved by the National Pharmaceutical Regulatory Division (NPRA) on May 28. The third phase of the clinical study of this vaccine would be conducted in eight research centres in Malaysia targeting the participation of 3,000 adults aged 18 and above and was expected to take 15 to 19 months, he said. “The Health Ministry would like to inform that there is an addition of one clinical study, involving the product SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL manufactured by Shenzhen Kangtai Biological Products Co Ltd from China.